Feline
Update (June 17, 2026): Maropitant Equals Ondansetron and Metoclopramide for Dexmedetomidine-Induced Vomiting in Cats — Head-to-Head RCT
TL;DR
A 2025 randomised trial in 64 cats found that maropitant, ondansetron, and metoclopramide each significantly reduced retching and vomiting triggered by dexmedetomidine premedication, with no significant difference in efficacy among the three antiemetic agents.
What just dropped
- Golbeli Bedir et al. 2025 (Vet Med Sci 11(1):e70152, January 2025; DOI 10.1002/vms3.70152; PMID 39792081; open access): 64 cats randomly allocated to receive saline, maropitant, ondansetron, or metoclopramide 30 minutes before dexmedetomidine administration.
- Duration and severity of vomiting were significantly reduced in the maropitant, ondansetron, and metoclopramide groups compared with the saline control group.
- Retching and vomiting were significantly reduced in the three antiemetic groups versus saline (p<0.001). No significant differences in sialorrhoea or lip licking were observed across groups (p=0.34 and p=0.12, respectively).
- No significant difference in antiemetic efficacy was found among the maropitant, ondansetron, and metoclopramide groups for prevention of dexmedetomidine-induced vomiting in cats.
Context
Dexmedetomidine-induced vomiting is a common perioperative concern in cats, occurring with medetomidine and dexmedetomidine sedation protocols before induction. The Golbeli Bedir 2025 trial directly compares three commonly used antiemetic agents in a randomised design, providing clinician-level data on comparative efficacy in this specific setting.
The finding that maropitant showed no superiority over ondansetron or metoclopramide in this context is notable given the mechanistic distinction: maropitant acts as an NK1 receptor antagonist (blocking substance P) whereas ondansetron blocks 5-HT3 receptors and metoclopramide is a dopamine D2 antagonist and prokinetic. All three appear to effectively block the emetic response downstream of alpha-2 adrenoceptor stimulation by dexmedetomidine in cats.
This does not diminish the specific visceral-analgesia evidence for maropitant in perioperative pain contexts (as covered in separate literature), but it clarifies that for the narrow indication of dexmedetomidine-induced emesis prevention, maropitant does not appear to have a mechanism-based advantage.
What this changes in maropitant-dogs-cats-vomiting (https://www.thevoyage.ai/forvets/knowledge/maropitant-dogs-cats-vomiting)
The Golbeli Bedir 2025 RCT adds head-to-head comparative antiemetic data for a common clinical scenario (dexmedetomidine-induced vomiting in cats). It confirms maropitant is effective in this setting but clarifies it offers no measurable advantage over ondansetron or metoclopramide for this specific indication. Clinician choice among these agents in this context may appropriately be guided by availability, cost, and route preferences rather than efficacy differentiation.
References
- Golbeli Bedir A, Yanmaz LE, Okur S, et al. The Effect of Maropitant, Ondansetron and Metoclopramide on Dexmedetomidine-Induced Vomiting in Cats. Vet Med Sci. 2025 Jan;11(1):e70152. DOI: 10.1002/vms3.70152 (https://doi.org/10.1002/vms3.70152)
Related reads
References
More clinical updates
Update (June 17, 2026): Adjunctive FMT Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis — First RCT
A June 2026 double-blinded RCT (40 dogs) found adjunctive faecal microbiota transplantation reduced CADESI-04 scores and medication requirements in cAD versus placebo.
Read →Update (June 17, 2026): Lymph Food RCT Improves Lesion Scores and Reduces Medication Use in Dogs with Atopic Dermatitis
Frizzo-Ramos 2025 (112-day RCT, 38 dogs): lymph food supplement added to standard cAD care reduced CADESI-4 by 55% vs +26% placebo (p<0.0003) and cut medication use.
Read →Update (June 17, 2026): Bedinvetmab Plus Physiotherapy Outperforms Bedinvetmab Alone on Pain Threshold in Dogs With Hip OA
Cidral 2026 RCT (30 dogs): bedinvetmab + photobiomodulation/PEMF superior to bedinvetmab alone on algometry from Day 30 (p=0.027), more pronounced at D60-90 (p<0.001).
Read →Update (June 17, 2026): Survey of 373 Vets Finds Wide Canine OA Practice Variation — Bedinvetmab Paresis/Ataxia Signal at 31%
Bird 2026 survey (373 vets): NSAIDs dominate canine OA Rx; bedinvetmab perceived neurological AEs at 31%; grapiprant GI AEs (diarrhea 33%, vomiting 31%) most reported.
Read →